Benign Prostatic Hyperplasia Treatment Market - Scope of the Study
This research quantifies the growth of the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027. This exclusive research report on the global benign prostatic hyperplasia treatment market offers a detailed overview of the market, uncovering significant aspects and segmentations based on numerous parameters. This comprehensive research report also talks about the research methodologies being adopted in order to estimate precise market numbers. This detailed business guide also includes relevant charts and tables, in order to enable stakeholders get an incisive outlook of the market for the forecast period.
This statistical business report analyzes, at length, crucial insights obtained by this exclusive study. With the aid of rare and distinguished insights enumerated in this comprehensive research report, stakeholders in the market can form business growth strategies to gain an upper hand over their competitors. Various factors accounted for the benign prostatic hyperplasia treatment market’s upward growth trajectory are discussed at length in this research report. Additionally, the research report identifies and explains the key drivers, threats, restraints, and opportunities present in the market.
This broad study of the global benign prostatic hyperplasia treatment market assesses the growth drivers and restraints at length. This exhaustive study of important factors can aid market players in understanding the challenges present in the market during the forecast period of 2019-2027. The detailed research report gauges the bargaining power of buyers and suppliers, threats arising from new market entrants and substitutes, and the degree of competition present in the market. Influence exerted on the market by the government policies is also discussed in this research report.
Benign Prostatic Hyperplasia Treatment Market - Key Questions Answered
This comprehensive research report analyzes and answers crucial questions related to the growth of the benign prostatic hyperplasia treatment market during the forecast period. Some of the key questions answered in this study are as follows:
- What are the key developments and important market shifts expected to be observed in the market during the forecast period of 2019-2027?
- What are the key strategies followed by market participants functioning in the market?
- What are some of the important recent developments that the new market participants should look at?
- Which treatment will be the top-selling one in the market?
Benign Prostatic Hyperplasia Treatment Market - Research Methodology
The research approach taken by Analysts includes a robust methodology for obtaining key insights into the market for the forecast period of 2019-2027. Interviews were conducted with important market participants, opinion leaders, vendors, distributors, and industry experts. In addition to this, a detailed secondary study of company websites, industry associations, marketing collaterals, and government statistics is carried out.
Note: Product cover images may vary from those shown
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
3.2. Global Benign Prostatic Hyperplasia Treatment Market: Market Snapshot
4. Market Overview
4.1. Global Benign Prostatic Hyperplasia Treatment Market: Treatment Overview
4.2. Global Benign Prostatic Hyperplasia Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.4. Drivers and Restraints Snapshot Analysis
4.5. Drivers
4.5.1. Increasing Aging Men Population All Over the World
4.5.2. Expanding Patient Pool Due to Other Risk Factors
4.6. Restraints
4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition
4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs
4.7. Opportunities
4.8. Global Benign Prostatic Hyperplasia Treatment Market Revenue Projections (US$ Mn), 2017-2027
5. Key Insights
5.1. Clinical Trial Pipeline Analysis
5.2. U.S. Prevalence of Benign Prostatic Hyperplasia
5.3. Re-imbursement Scenario
5.4. Key Merger and Acquisitions
5.5. Number of Surgeries (Unit Procedures) Performed, 2018
5.6. Competitive Market Share Analysis, by Company, 2018
5.7. Average Cost of Benign Prostatic Hyperplasia Treatment
5.8. Product/Brand Analysis - 2018
5.8.1. Urolift
5.8.2. Rezum
6. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
6.2.1. Drug Class
6.2.1.1. Alpha-blockers
6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
6.2.1.4. Others
6.2.2. Minimally Invasive Surgeries
6.2.2.1. Transurethral Resection of the Prostate (TURP)
6.2.2.2. Transurethral Incision of the Prostate (TUIP)
6.2.2.3. Robotic Surgeries
6.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
6.2.2.5. Prostatic Urethral Lift
6.2.2.6. Others
6.2.3. Laser Therapy
6.2.4. Others
6.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
6.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment
7. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
7.1. Introduction
7.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
7.2.1. Hospitals
7.2.2. Ambulatory Surgical Centers
7.2.3. Specialty Clinics
7.2.4. Others
7.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
7.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user
8. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
8.1. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Region, 2017-2027
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
8.3. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Region
9. North America Benign Prostatic Hyperplasia Treatment Market Analysis
9.1. North America Benign Prostatic Hyperplasia Treatment Market
9.2. North America Benign Prostatic Hyperplasia Treatment Market Overview
9.3. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
9.3.1. Drug Class
9.3.1.1. Alpha-blockers
9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
9.3.1.4. Others
9.3.2. Minimally Invasive Surgeries
9.3.2.1. Transurethral Resection of the Prostate (TURP)
9.3.2.2. Transurethral Incision of the Prostate (TUIP)
9.3.2.3. Robotic Surgeries
9.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
9.3.2.5. Prostatic Urethral Lift
9.3.2.6. Others
9.3.3. Laser Therapy
9.3.4. Others
9.3.5.
9.4. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Centers
9.4.3. Specialty Clinics
9.4.4. Others
9.5. North America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By End-user
9.6.3. By Country
10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis
10.1. Europe Benign Prostatic Hyperplasia Treatment Market
10.2. Europe Benign Prostatic Hyperplasia Treatment Market Overview
10.3. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
10.3.1. Drug Class
10.3.1.1. Alpha-blockers
10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
10.3.1.4. Others
10.3.2. Minimally Invasive Surgeries
10.3.2.1. Transurethral Resection of the Prostate (TURP)
10.3.2.2. Transurethral Incision of the Prostate (TUIP)
10.3.2.3. Robotic Surgeries
10.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
10.3.2.5. Prostatic Urethral Lift
10.3.2.6. Others
10.3.3. Laser Therapy
10.3.4. Others
10.4. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Specialty Clinics
10.4.4. Others
10.5. Europe Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
10.5.1. U.K.
10.5.2. France
10.5.3. Germany
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis
11.1. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Key Findings
11.2. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Overview
11.3. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
11.3.1. Drug Class
11.3.1.1. Alpha-blockers
11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
11.3.1.4. Others
11.3.2. Minimally Invasive Surgeries
11.3.2.1. Transurethral Resection of the Prostate (TURP)
11.3.2.2. Transurethral Incision of the Prostate (TUIP)
11.3.2.3. Robotic Surgeries
11.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
11.3.2.5. Prostatic Urethral Lift
11.3.2.6. Others
11.3.3. Laser Therapy
11.3.4. Others
11.4. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Specialty Clinics
11.4.4. Others
11.5. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis
12.1. Latin America Benign Prostatic Hyperplasia Treatment Market Key Findings
12.2. Latin America Benign Prostatic Hyperplasia Treatment Market Overview
12.3. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
12.3.1. Drug Class
12.3.1.1. Alpha-blockers
12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
12.3.1.4. Others
12.3.2. Minimally Invasive Surgeries
12.3.2.1. Transurethral Resection of the Prostate (TURP)
12.3.2.2. Transurethral Incision of the Prostate (TUIP)
12.3.2.3. Robotic Surgeries
12.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
12.3.2.5. Prostatic Urethral Lift
12.3.2.6. Others
12.3.3. Laser Therapy
12.3.4. Others
12.4. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Specialty Clinics
12.4.4. Others
12.5. Latin America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis
13.1. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
13.2. Benign Prostatic Hyperplasia Treatment Market Overview
13.3. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
13.3.1. Drug Class
13.3.1.1. Alpha-blockers
13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
13.3.1.4. Others
13.3.2. Minimally Invasive Surgeries
13.3.2.1. Transurethral Resection of the Prostate (TURP)
13.3.2.2. Transurethral Incision of the Prostate (TUIP)
13.3.2.3. Robotic Surgeries
13.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
13.3.2.5. Prostatic Urethral Lift
13.3.2.6. Others
13.3.3. Laser Therapy
13.3.4. Others
13.4. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Specialty Clinics
13.4.4. Others
13.5. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competitive Landscape (Pharmaceutical Companies)
14.1. Company Profiles
14.1.1. Abbott
14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
14.1.1.2. Financials
14.1.1.3. Recent Developments
14.1.1.4. Strategy
14.1.2. Allergan plc
14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
14.1.2.2. Financials
14.1.2.3. Recent Developments
14.1.2.4. Strategy
14.1.3. Astellas Pharma, Inc.
14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
14.1.3.2. Financials
14.1.3.3. Recent Developments
14.1.3.4. Strategy
14.1.4. Asahi Kasei Corporation
14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
14.1.4.2. Financials
14.1.4.3. Recent Developments
14.1.4.4. Strategy
14.1.5. Boehringer Ingelheim GmbH
14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
14.1.5.2. Financials
14.1.5.3. Recent Developments
14.1.5.4. Strategy
14.1.6. GlaxoSmithKline plc
14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
14.1.6.2. Financials
14.1.6.3. Recent Developments
14.1.6.4. Strategy
14.1.7. Pfizer, Inc.
14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
14.1.7.2. Financials
14.1.7.3. Recent Developments
14.1.7.4. Strategy
14.1.8. Sanofi
14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
14.1.8.2. Financials
14.1.8.3. Recent Developments
14.1.8.4. Strategy
14.1.9. Teva Pharmaceutical Industries Ltd.
14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
14.1.9.2. Financials
14.1.9.3. Recent Developments
14.1.9.4. Strategy
14.1.10. Merck & Co., Inc.
14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
14.1.10.2. Financials
14.1.10.3. Recent Developments
14.1.10.4. Strategy
15. Competitive Landscape (Medical Devices/Service Provider Organizations)
15.1. Company Profiles
15.1.1. Boston Scientific Corporation
15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
15.1.1.2. Financials
15.1.1.3. Recent Developments
15.1.1.4. Strategy
15.1.2. Teleflex Incorporated
15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
15.1.2.2. Financials
15.1.2.3. Recent Developments
15.1.2.4. Strategy
15.1.3. Endo International plc
15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
15.1.3.2. Financials
15.1.3.3. Recent Developments
15.1.3.4. Strategy
15.1.4. Urologix, LLC
15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
15.1.4.2. Financials
15.1.4.3. Recent Developments
15.1.4.4. Strategy
15.1.5. LISA Laser
15.1.5.1. Overview (HQ, Employee Strength, Business Segments)
15.1.5.2. Financials
15.1.5.3. Recent Developments
15.1.5.4. Strategy
15.1.6. Olympus Corporation
15.1.6.1. Overview (HQ, Employee Strength, Business Segments)
15.1.6.2. Financials
15.1.6.3. Recent Developments
15.1.6.4. Strategy
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
3.2. Global Benign Prostatic Hyperplasia Treatment Market: Market Snapshot
4. Market Overview
4.1. Global Benign Prostatic Hyperplasia Treatment Market: Treatment Overview
4.2. Global Benign Prostatic Hyperplasia Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.4. Drivers and Restraints Snapshot Analysis
4.5. Drivers
4.5.1. Increasing Aging Men Population All Over the World
4.5.2. Expanding Patient Pool Due to Other Risk Factors
4.6. Restraints
4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition
4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs
4.7. Opportunities
4.8. Global Benign Prostatic Hyperplasia Treatment Market Revenue Projections (US$ Mn), 2017-2027
5. Key Insights
5.1. Clinical Trial Pipeline Analysis
5.2. U.S. Prevalence of Benign Prostatic Hyperplasia
5.3. Re-imbursement Scenario
5.4. Key Merger and Acquisitions
5.5. Number of Surgeries (Unit Procedures) Performed, 2018
5.6. Competitive Market Share Analysis, by Company, 2018
5.7. Average Cost of Benign Prostatic Hyperplasia Treatment
5.8. Product/Brand Analysis - 2018
5.8.1. Urolift
5.8.2. Rezum
6. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
6.2.1. Drug Class
6.2.1.1. Alpha-blockers
6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
6.2.1.4. Others
6.2.2. Minimally Invasive Surgeries
6.2.2.1. Transurethral Resection of the Prostate (TURP)
6.2.2.2. Transurethral Incision of the Prostate (TUIP)
6.2.2.3. Robotic Surgeries
6.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
6.2.2.5. Prostatic Urethral Lift
6.2.2.6. Others
6.2.3. Laser Therapy
6.2.4. Others
6.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
6.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment
7. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
7.1. Introduction
7.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
7.2.1. Hospitals
7.2.2. Ambulatory Surgical Centers
7.2.3. Specialty Clinics
7.2.4. Others
7.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
7.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user
8. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
8.1. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Region, 2017-2027
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
8.3. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Region
9. North America Benign Prostatic Hyperplasia Treatment Market Analysis
9.1. North America Benign Prostatic Hyperplasia Treatment Market
9.2. North America Benign Prostatic Hyperplasia Treatment Market Overview
9.3. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
9.3.1. Drug Class
9.3.1.1. Alpha-blockers
9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
9.3.1.4. Others
9.3.2. Minimally Invasive Surgeries
9.3.2.1. Transurethral Resection of the Prostate (TURP)
9.3.2.2. Transurethral Incision of the Prostate (TUIP)
9.3.2.3. Robotic Surgeries
9.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
9.3.2.5. Prostatic Urethral Lift
9.3.2.6. Others
9.3.3. Laser Therapy
9.3.4. Others
9.3.5.
9.4. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Centers
9.4.3. Specialty Clinics
9.4.4. Others
9.5. North America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By End-user
9.6.3. By Country
10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis
10.1. Europe Benign Prostatic Hyperplasia Treatment Market
10.2. Europe Benign Prostatic Hyperplasia Treatment Market Overview
10.3. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
10.3.1. Drug Class
10.3.1.1. Alpha-blockers
10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
10.3.1.4. Others
10.3.2. Minimally Invasive Surgeries
10.3.2.1. Transurethral Resection of the Prostate (TURP)
10.3.2.2. Transurethral Incision of the Prostate (TUIP)
10.3.2.3. Robotic Surgeries
10.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
10.3.2.5. Prostatic Urethral Lift
10.3.2.6. Others
10.3.3. Laser Therapy
10.3.4. Others
10.4. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Specialty Clinics
10.4.4. Others
10.5. Europe Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
10.5.1. U.K.
10.5.2. France
10.5.3. Germany
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis
11.1. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Key Findings
11.2. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Overview
11.3. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
11.3.1. Drug Class
11.3.1.1. Alpha-blockers
11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
11.3.1.4. Others
11.3.2. Minimally Invasive Surgeries
11.3.2.1. Transurethral Resection of the Prostate (TURP)
11.3.2.2. Transurethral Incision of the Prostate (TUIP)
11.3.2.3. Robotic Surgeries
11.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
11.3.2.5. Prostatic Urethral Lift
11.3.2.6. Others
11.3.3. Laser Therapy
11.3.4. Others
11.4. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Specialty Clinics
11.4.4. Others
11.5. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis
12.1. Latin America Benign Prostatic Hyperplasia Treatment Market Key Findings
12.2. Latin America Benign Prostatic Hyperplasia Treatment Market Overview
12.3. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
12.3.1. Drug Class
12.3.1.1. Alpha-blockers
12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
12.3.1.4. Others
12.3.2. Minimally Invasive Surgeries
12.3.2.1. Transurethral Resection of the Prostate (TURP)
12.3.2.2. Transurethral Incision of the Prostate (TUIP)
12.3.2.3. Robotic Surgeries
12.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
12.3.2.5. Prostatic Urethral Lift
12.3.2.6. Others
12.3.3. Laser Therapy
12.3.4. Others
12.4. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Specialty Clinics
12.4.4. Others
12.5. Latin America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis
13.1. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
13.2. Benign Prostatic Hyperplasia Treatment Market Overview
13.3. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
13.3.1. Drug Class
13.3.1.1. Alpha-blockers
13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
13.3.1.4. Others
13.3.2. Minimally Invasive Surgeries
13.3.2.1. Transurethral Resection of the Prostate (TURP)
13.3.2.2. Transurethral Incision of the Prostate (TUIP)
13.3.2.3. Robotic Surgeries
13.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
13.3.2.5. Prostatic Urethral Lift
13.3.2.6. Others
13.3.3. Laser Therapy
13.3.4. Others
13.4. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Specialty Clinics
13.4.4. Others
13.5. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competitive Landscape (Pharmaceutical Companies)
14.1. Company Profiles
14.1.1. Abbott
14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
14.1.1.2. Financials
14.1.1.3. Recent Developments
14.1.1.4. Strategy
14.1.2. Allergan plc
14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
14.1.2.2. Financials
14.1.2.3. Recent Developments
14.1.2.4. Strategy
14.1.3. Astellas Pharma, Inc.
14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
14.1.3.2. Financials
14.1.3.3. Recent Developments
14.1.3.4. Strategy
14.1.4. Asahi Kasei Corporation
14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
14.1.4.2. Financials
14.1.4.3. Recent Developments
14.1.4.4. Strategy
14.1.5. Boehringer Ingelheim GmbH
14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
14.1.5.2. Financials
14.1.5.3. Recent Developments
14.1.5.4. Strategy
14.1.6. GlaxoSmithKline plc
14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
14.1.6.2. Financials
14.1.6.3. Recent Developments
14.1.6.4. Strategy
14.1.7. Pfizer, Inc.
14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
14.1.7.2. Financials
14.1.7.3. Recent Developments
14.1.7.4. Strategy
14.1.8. Sanofi
14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
14.1.8.2. Financials
14.1.8.3. Recent Developments
14.1.8.4. Strategy
14.1.9. Teva Pharmaceutical Industries Ltd.
14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
14.1.9.2. Financials
14.1.9.3. Recent Developments
14.1.9.4. Strategy
14.1.10. Merck & Co., Inc.
14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
14.1.10.2. Financials
14.1.10.3. Recent Developments
14.1.10.4. Strategy
15. Competitive Landscape (Medical Devices/Service Provider Organizations)
15.1. Company Profiles
15.1.1. Boston Scientific Corporation
15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
15.1.1.2. Financials
15.1.1.3. Recent Developments
15.1.1.4. Strategy
15.1.2. Teleflex Incorporated
15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
15.1.2.2. Financials
15.1.2.3. Recent Developments
15.1.2.4. Strategy
15.1.3. Endo International plc
15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
15.1.3.2. Financials
15.1.3.3. Recent Developments
15.1.3.4. Strategy
15.1.4. Urologix, LLC
15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
15.1.4.2. Financials
15.1.4.3. Recent Developments
15.1.4.4. Strategy
15.1.5. LISA Laser
15.1.5.1. Overview (HQ, Employee Strength, Business Segments)
15.1.5.2. Financials
15.1.5.3. Recent Developments
15.1.5.4. Strategy
15.1.6. Olympus Corporation
15.1.6.1. Overview (HQ, Employee Strength, Business Segments)
15.1.6.2. Financials
15.1.6.3. Recent Developments
15.1.6.4. Strategy
Note: Product cover images may vary from those shown
